Background:
INTRODUCTION
Lymphedema is a debilitating condition resulting from dysfunction of lymphatic system characterised by progressive soft tissue swelling which commonly involves the limbs and genitalia. Lymphedema is categorised into primary and secondary lymphedema. Primary lymphedema is rare and caused by genetic defects. Secondary lymphedema is common and caused by acquired damage secondary to surgical resection (lymph node clearance), tumour infiltration, parasitic infection and radiation induced fibrosis.
In the United Kingdom alone, there are estimated 240,000 people living with lymphedema (1). Despite the wide practise of breast conserving surgery and minimal lymphatic intervention, the world wide incidence of secondary lymphedema remains high with an estimate of 295,320 patients developing upper limb lymphedema yearly after breast cancer surgery (2). This huge number highlights the critical clinical need to treat surgery induced secondary lymphedema.
The current armamentarium of therapeutic intervention involves non-surgical and surgical treatment. Non-surgical treatment includes bandaging and physiotherapy which does not prevent progression of disease and results in poor quality of life. The surgical treatment of lymphedema has evolved tremendously over the years. In 1990, Baumeister reported the use of lymphatic (lymphatico-lymphatic) bypass graft to bridge damaged lymphatic vessels utilising autologous lymphatic graft harvested from ventromedial part of the thigh (3).
Although reporting a volume reduction of 80% compared to pre-operative conditions, this technique did not gain popularity due to the high risk of donor site morbidity. Following the same principle, Campisi used vein graft (lymphatic-venous-lymphatic shunt) and reported volume reduction of 75% in almost half of his patients(4). Several other form of surgical treatment such as liposuction (suction assisted lipectomy), subcutaneous excision and ablative surgery with skin grafting were practiced but with poor outcomes. In the recent years, surgical treatment of lymphedema has evolved into super-microsurgical approach. The techniques undertaken are lymphatic bypass surgery (lymphaticovenular anastomosis) and vascularised lymph node transfer. Most authors reported a modest improvement in limb volumes (decrease of 30%-50%) although some patients experienced more significant improvement (5). However, none of these techniques are curative and they are exclusively for patients in early stages of lymphedema. Intrinsic contraction of lymphatic vessel ranges between 12 and 70mmHg in healthy human.
The extrinsic pressure in healthy human ranges between 0 and 60mmHg (18). In pathological condition, the intrinsic lymphatic pressure is elevated and the accumulation of fibrotic tissue as well as adipocytes due to lymph stasis drastically alters the surrounding mechanical environment (19, 20) . This condition may eventually overwhelm the lymphatic vessels and result in decreased contractile tone and frequency of collecting lymphatics as seen in rat thoracic duct model (negative chronotrophic and inotrophic effect) (21). However, this is not seen in the mesenteric lymphatic vessels which indicated that the amount of reduction varies in different location. The pressure gradient at which flow cessation takes place in human is yet to be known. It is crucial to quantify these values in diseased human lymphatic system as the ability to simulate these pressure ex-vivo is paramount in determining the success of the lymphatic graft.
The advancement of imaging modalities coupled with computational power and image processing algorithms has enabled reliable quantification and correlation between lymph flow rate and intrinsic contractile activity (11, 12). The use of non-invasive imaging modalities, the near-infrared (NIR) fluorescence imaging in combination with the clinically approved Indocyanine Green (ICG) dye has enabled researchers to better understand the draining velocity of initial lymphatics and contractile physiology of collecting lymphatics in human as most previous studies were mostly limited to animal models(13-15). This advancement in imaging has been particularly useful in understanding the changes that takes place in diseased lymphatic system which is a step closer to unravelling ways to manipulate the biological and mechanical changes taking place in lymphedema. 
lymphatic Valve
The main challenge in the design of artificial lymphatic graft is the inclusion of valves.
Lymphatic valves are bileaflet and made up of connective tissue lined by LECs which are anchored to the base by elastin and collagen that are responsible to resist inversion (26).
Valves are present at intervals of every few millimetres and usually found in vessel bifurcations and branch points (27, 28). Valves function to prevent backflow and is the anatomical site of fluid shear sensation for production of nitric oxide to regulate lymphatic contractions (29). Valvular dysfunction would exacerbate lymphedema which is witnessed in genetic conditions involving lymphatic valve malformation such as in FOXC2 mutation (30).
Valves also play an important role in sectioning the conduit into shorter segments in order to assist capillary action.
Capillary action is described as (31):
Where h is the height of the meniscus, θ is the contact angle, γ is the liquid-air surface tension (force/unit length), g is the gravitational acceleration (length/square of time), p is the density of liquid (mass/volume), and r is the radius of conduit (length). Equation (a) implies that height of capillary action is inversely proportional to the radius of the conduit. A simplified assumption using properties of water suggests that the height of capillary action is 3.6cm if the r is 0.4mm. However, knowing that the density of lymph is greater than that of water, the height of meniscus is expected to be much lower and hence capillary action alone is insufficient to drive the lymph through the whole length of lymphatic vessels if valves were not present to segment the columns.
Scaffold
Tissue engineering is aimed at creating a construct which allows harmonious interaction between scaffold, cells and appropriate growth factors (32). An ideal scaffold should bridge the gap between lymphatic vessels and guide regeneration of functional lymphatic tissue. The importance of designing a conduit with intraluminal valves exclude the possibility of using non-scaffold based tissue engineering approach such as 'sheet-based' method (22). Scaffold for lymphatic graft can be broadly divided into synthetic and natural (decellularized).
Biodegradable synthetic scaffold
Synthetic scaffold has the advantage of being custom designed and shaped with well-defined physical and biochemical property at production. Biodegradable synthetic scaffold acts as temporary scaffold prior to being substituted by cellular matrix that is balanced by the polymer degradation rate. Polyglycolic acid (PGA) scaffold was used by Dai and colleagues to engineer lymphatic vessel and reported successful endothelialization by LEC (33). PGA was used due to its well documented biocompatibility as well as the ease in manipulating and design. This is the sole reported work on biodegradable lymphatic conduit and despite being a preliminary work; it showed the ability of LEC to attach onto polymer scaffold.
Non-biodegradable synthetic scaffold
This scaffold has stable mechanical strength and able to maintain its shape. The main issue with most of these materials used in vascular grafts are maintaining patency of the graft and high infection rate especially when the diameter is <5mm (34, 35). This is due to the absence of adaptive tissue that is responsive to local environment (36). These limitations have driven Surface topography that is favourable for LEC has yet to be outlined but this feature has been extensively explored with regards to vascular graft engineering. Nanostructuralisation increases total surface area which in return facilitates protein interaction and promotes cell adhesion (54). 
3.6
Growth factor
Regenerative medicine research is likely to produce more effective and better tolerated treatment for lymphedema in the long term and proper understanding of lymphangiogenesis is the essence of it. Lymphangiogenesis occurs physiologically during wound healing as well as pathologically in inflammation, tumours metastasis and transplant rejection (59, 60). Table 2 and 3 provides a comprehensive summary of the main molecular factors found to be important in normal lymphatic development, function and maintenance.
In pathological condition such as lymphedema, the vascular endothelial growth factor-C (VEGF-C) expression or even over-expression is insufficient to promote lymphatic regeneration (61, 62). In such cases, lymphatic function and regeneration could be improved by inhibition of transforming growth factor beta-1 (TGF-β1) (63). The TGF-β1 has potent anti-lymphangiogenic activity leading to decreased LEC proliferation and in vivo LEC migration, impaired lymphatic tubule formation and down regulation of lymphatic specific gene expression (63). Furthermore, the uses of anti-lymphangiogenic factors are also clinically relevant in cases where VEGF-C is contraindicated such as in immediate post cancer resection since VEGF-C expression could contribute to tumour growth and metastasis (64). Hence tissue engineering approach could augment lymphangiogenesis by regulating the equilibrium between lymphangiogenic and anti-lymphangiogenic forces.
Gene therapy
Genetic and recombinant protein therapeutic strategies are likely to enhance lymphangiogenesis and treat both primary and secondary lymphedema. Hepatocyte growth factor (HGF) gene therapy has successfully stimulated the growth of lymphatic vascular system in mouse model (65). HGF plasmid DNA was used in vascular system, heart and lung and also reported to be safe in patients with critical limb ischaemia (66, 67). Besides that, VEGF-C activation using viral vectors also reported to have potential in lymphedema treatment (68). However, VEGF-C therapy was reported to exacerbate oedema by causing REVISED REVISION DATE: 09/07/2014 poor functioning and hyperplastic lymphatic vessels(62). Nevertheless, gene therapy and growth factors have the potential to be an adjunct to engineered biomaterials which can be administered locally or systemically to enhance collateral lymphatic vessel formation and also to provide greater biocompatibility for the biomaterial.
3.8
Cell source
Common source of LEC isolation is the skin dermis and its isolation from human dermis has 
CONCLUSION AND FUTURE PROSPECTIVE
Treatment of lymphedema is evolving positively of late due to the growing knowledge in lymphatic biology which has enhanced our understanding on lymphatic growth and repair. In conjunction with this, more studies need to be carried out to further characterise the human lymphatic system in order to bridge the current limitations that exit alongside the promise that new technological advancement holds. Tissue engineered lymphatic graft is a tool that could benefit many around the world by reducing the morbidity related to lymphedema. (^gene mutation related to known cases of human primary lymphedema)
Molecular factor Function References
Emilin-1 (elastic extra- Essential in lymphatic development in a zebra fish, recent link to human primary lymphedema.
Has not been found to be expressed in lymphatic endothelium and is more likely to be found within the ECM. 
